is known about the function of the apelinergic system during gestation. In this study, we evaluated in rats the activity of this system, the role of apelin in fetal and neonatal glucose homeostasis and its modulation by maternal food-restriction (FR). We found that: 1/ the apelinergic system is expressed at the fetoplacental interface and in numerous fetal tissues, 2/ ex-vivo, the placenta releases high amount of apelin in late gestation, 3/ i.v. apelin injection in mothers increases the transplacental transport of glucose, 4/ i.p. apelin administration in neonates increases glucose uptake in lung and muscle. Maternal FR drastically reduced apelinemia in both mother and growth-restricted fetuses and altered the expression of the apelinergic system at the fetoplacental interface. Together, our data demonstrate that apelin controls fetal and neonatal glucose homeostasis and is altered by fetal growth restriction induced by maternal undernutrition.
Introduction
Apelin is a regulatory peptide, identified as an endogenous ligand of the apelin receptor named APJ (1) . Apelin gene encodes a 77-amino-acid preproprotein that generates during posttranslational processing several molecular isoforms such as apelin-36, apelin-17 and apelin-13 (2; 3). Moreover, the N-terminal glutamate of apelin-13 can be posttranslationally modified thus creating the pyroglutamate apelin-13 ([pyr-1]-apelin-13) which is more protected from exopeptidase degradation (4) . Apelin and APJ have a widespread distribution in the body and are involved in various physiological functions. Apelin and APJ mRNAs are expressed in heart, lung, placenta, mammary gland, several regions of the central nervous system, adipocytes and the gastrointestinal tract (5; 6) . Depending on the cell type studied, APJ activation results in the activation of several intracellular effectors such as Extracellular signal-Regulated Kinases (ERKs), protein kinase B (PKB or Akt) and p70S6 kinase; but also in the inhibition of cAMP production (7; 8) .
Recently, apelin has been extensively described as a beneficial factor regarding to glucose metabolism and is endowed with anti-diabetic properties (9; 10) . Studies demonstrated that both short-and long-term apelin treatments improve insulin sensitivity in obese and insulin-resistant mice mainly by increasing glucose uptake in skeletal muscle (9) (10) (11) . Apelin also modulates insulin secretion and increases pancreatic islet cell mass and β-cell insulin content in mice (12) . During prenatal development, previous studies have revealed that APJ deficiency in mice causes early embryonic defects and leads to embryonic lethality due to growth retardation and cardiac malformations (13) . However, the effect of apelin on glucose homeostasis in utero remains unknown. To gain further insight into apelin function during gestation and to study the effects of apelin on fetal and neonatal glucose homeostasis, the aims of the present study were to investigate in rats: 1/ the kinetics of apelin plasma levels in mother/fetus pairs, 2/ the ex-vivo placental apelin release, 3/ the gene expression levels of apelin and APJ in the fetoplacental unit, 4/ the effect of maternal apelin administration on transplacental glucose transfer and 5/ the effect of apelin administration to neonates on glucose uptake in several tissues. We subsequently studied the apelinergic (apelin and APJ) system in intrauterine growth-restricted (IUGR) fetuses from rat mothers that received only 30% of the food-intake of control mothers (FR30 model).
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Placental apelin secretion.
After cesarean section, E17 and E21 placentas (n=24) were collected rinsed in saline and incubated for 24 hours in dish plates containing 2 ml of DMEM (Gibco). Dish plates were placed at 37°C with 95% O2/5% CO2 and 95% humidity. Samples of medium were collected after 2, 6 and 24h of incubation for determination of apelin concentrations. 
In Vivo 2-deoxy-D-[ 3 H] glucose incorporation in neonatal tissues

An intraperitoneal injection of 50 µCi of 2-deoxy-D-[3H] glucose in saline or
associated with [pyr-1]-apelin-13 (15 nmol/kg) was performed in rat neonates at birth (n=14).
After 30 min, rats were decapitated and 7 selected tissues were collected for [ 3 H]-2DG uptake determination.
Statistical analysis
Results are reported as means ± SEM. Statistical analyses were performed using one way ANOVA and Dunnett's test. A P value of less than 0.05 was considered significant.
Plasma and expression levels of apelin and APJ in the rat fetoplacental unit
Maternal plasma apelin concentrations were decreased at E7, increased from E7 to E17 and reduced at term (Fig. 1A) . Fetal plasma apelin concentrations were 2-fold higher than maternal levels at E17 while they were similar at E21 (Fig. 1B) . Apelin mRNA levels were higher in the Meso-tr compared to placenta at E13 and thereafter reduced until term of gestation in both tissues (Fig. 1C) . APJ mRNA levels were similar in these two tissues at E13 (Fig. 1D) . In the placenta, APJ expression was increased at E17 vs E13 level and reduced at E21 whereas in the Meso-tr an opposite modulation was observed (Fig. 1D) . Ex-vivo, rat placentas released increasing quantities of apelin during 24h and this secretion was approximately twice higher at E17 than at E21 (Fig. 2A) .
Apelin stimulates transplacental glucose transport and glucose uptake in fetus
Using [ 3 H]-2DG as a tracer, we showed that apelin-13 i.v. administration to E17
females did not significantly affect placental glucose content ( Fig. 2B ) but significantly increased fetal glucose uptake (Fig. 2C ) without affecting placental GLUT1 and GLUT3 mRNA levels (Fig. 2D) . In E21 fetuses, tissue distribution of apelin and APJ mRNAs demonstrated high expression levels in lung, heart, brain, kidney, stomach, muscle and testis ( Fig. 3A-3B) . A modest expression of this system was found in all others E21 tissues investigated ( Fig. 3A-3B ). Neonates injected with 10-15 nmol/kg of apelin-13 displayed a reduction in glycemia whereas the injection of higher doses of apelin-13 caused an increase in glycemia ( Fig. 3C ) and a reduction of insulinemia (Fig. 3D) . Concomitant administration of apelin-13 (at 15 nmol/kg) and [ 3 H]-2DG demonstrated that apelin has a powerful glucoselowering effect by enhancing glucose uptake in skeletal muscle and lung (Fig. 3E) .
Effects of maternal food restriction on fetal growth and the apelin/APJ system FR30 reduced both maternal and fetal body weights from E13 to E21 (Fig. 4A-C) .
FR30 reduced maternal plasma apelin concentrations from E13 to E21 (Fig. 4D ) and fetal plasma apelin concentrations at E17 (Fig. 4E) . Apelin mRNA levels were up-regulated at E17
in FR30 placentas and Meso-Tr (Fig. 4F-4G ). APJ gene-expression was increased in FR30
placentas at E13 and reduced at E21 in FR30 placentas and Meso-Tr (Fig. 4H-4I ).
Discussion
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In the present study, we demonstrated that maternal apelinemia is augmented during gestation and that ex-vivo the placenta releases high amount of apelin at E17, a period which coincided with a peak secretion of apelin in both maternal and fetal plasmas. Moreover, we showed that maternal apelin i.v. administration increases the transplacental transport of glucose and that, in neonates, acute apelin i.p. injection has a powerful glucose-lowering effect associated with enhanced glucose uptake in lung and muscle.
We found that maternal apelin levels are decreased during the first week of gestation, increased gradually from E7 to E17 and reduced at term. This decline of apelinemia at term is related to an increase apelin clearance by the placental angiotensin-converting enzyme-related carboxypeptidase-2 (ACE2) which catabolized apelin in late-gestation (15) . In fetuses, we observed that apelin levels are twice higher than maternal level at E17 while they are similar at E21. This is consistent with studies in humans that show a similar doubled apelinemia in umbilical cord blood compared to maternal plasma apelin concentrations (16) . In newborn babies, a drop in apelin levels was found at neonatal day 1 (16) suggesting that the placenta may be a source of apelin. In accordance, the apelinergic system is expressed in several placental compartments in both rats (15) and humans (17) . In our study, we analyzed the gene expression level of this system in rat placentas and in mesometrial triangles from E13 to E21.
We observed that placental apelin gene expression is closely correlated to maternal apelin levels pointing out to the potential placental origin of maternal apelin. To test this hypothesis, we studied the apelin release from placenta ex-vivo. We demonstrated that rat placentas are able to release significant amount of apelin and that this secretion is twice higher at E17 than at term (E21). This secretion coincided with a peak secretion of apelin in both maternal and fetal plasmas at E17 suggesting that this organ is a source of circulating apelin. This interpretation is in accordance with data from Van Mieghem et al. (15) showing that, in rats, a fetoplacental reduction significantly reduced maternal apelin levels.
Here, we report that the apelinergic system is expressed at the feto-maternal interface.
Of note, we observed a drastic increase in APJ placental gene expression between E13 and E17. We postulated that apelin may enhance transplacental nutrients transfer, more especially glucose transport. We found that apelin injection to E17 mothers increased transplacental glucose transport suggesting that maternal apelin levels control fetal glucose supply. This was observed without change in placental glucose transporters expressions. In rat placentas, apelin was detected in perivascular smooth muscle of the labyrinth suggesting that apelin may exert vasoactive action in the placenta (15) as it has been extensively reported for apelin in the periphery (18) (19) (20) . We propose that apelin may induce a vasodilatation of placental vessels which would enhance transplacental glucose transfer or that, indirectly, apelin may modulate maternal blood pressure resulting to this enhanced placental transport.
We observed high apelin levels in fetuses suggesting that apelin may be important for fetal development. In E21 fetuses, the apelin and APJ tissue-distribution was closely comparable to adults (5; 6; 21) with higher expressions found in lung, heart, muscle, brain, kidney, stomach and testis. Apelin injection to neonates was able at low dose to reduce glycemia and inversely to increase glycemia at high dose by inhibiting insulin release. These results are in accordance with the hypoglycemic effect of physiologic low doses of apelin in mice (11) and with the inhibitory role of high pharmacologic doses of apelin on insulin release (22) . We demonstrated that the hypoglycemic effect of apelin was associated with an increase in lung and muscle glucose uptakes. Similarly, in mice, apelin was shown to exert a powerful glucose-lowering effect associated with enhanced glucose utilization in skeletal muscle (11) .
Finally, we studied the apelinergic system in IUGR fetuses from FR30 mothers. FR30 drastically reduced maternal apelin levels from E13 to E21 as well as fetal apelin levels at E17. In accordance, plasma apelin concentrations were found to be reduced by foodrestriction in adult rodents and humans (9; 21) . In our FR30 model, we found that at the materno-fetal interface, apelin gene expression was up-regulated at E17. This phenomenon may be a compensatory response of IUGR fetuses to increase their glucose supply to improve their growth. All together, our data demonstrate that apelin is a new hormone implicated in fetal and neonatal glucose homeostasis. , P < 0.05 E7 vs NP values. B: Circulating apelin concentrations in mother/fetus pairs at E17 and E21 (n=6 litters/stage). (##) , P < 0.01 fetus vs mothers values. [++] , P < 0.01 E17 fetus vs E21 fetus values. C, D: Evolution of apelin and its receptor APJ mRNA levels at E13, E17 and E21 in the rat placenta and mesometrial triangle (Meso. Tr). , P < 0.01 FR30 vs control group (n=6 male fetuses from 6 independent litters/developmental stage).
